sodium glycinate | 6000-44-8

• 物质功能分类: 生物化工 - 常见氨基酸及蛋白质类
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: sodium glycinate
• 英文别名: glycine sodium salt；sodium glycine；glycine sodium；sodium;2-aminoacetate
• CAS: 6000-44-8
• 化学式: C₂H₄NO₂*Na
• 分子量: 97.049
• InChiKey: WUWHFEHKUQVYLF-UHFFFAOYSA-M

物化性质

• 沸点：
  321℃[at 101 325 Pa]
• 密度：
  1.333[at 20℃]
• LogP：
  -0.68
• 物理描述：
  Liquid

计算性质

• 辛醇/水分配系数(LogP)：
  -5.3
• 重原子数：
  6
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  66.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品运输编号：
  25kgs
• RTECS号：
  MC1100000
• 海关编码：
  2922499990
• 储存条件：
  室温

SDS

Name:	Glycine Sodium Salt Hydrate 99% Material Safety Data Sheet
Synonym:	Sodium Glycinate; Sodium Aminoacetate; Sodium Glycocollate
CAS:	6000-44-8

Section 1 - Chemical Product MSDS Name:Glycine Sodium Salt Hydrate 99% Material Safety Data Sheet
Synonym:Sodium Glycinate; Sodium Aminoacetate; Sodium Glycocollate

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
6000-44-8	Glycine, Sodium Salt Hydrate	99%	227-842-3

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation. The toxicological properties of this material have not been fully investigated.
Skin:
May cause skin irritation. The toxicological properties of this material have not been fully investigated.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation.
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 6000-44-8: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Chunks
Color: white granular
Odor: Traces of NH3
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 197 - 201 deg C
Autoignition Temperature: Not available.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water: SOLUBILITY IN METHANOL: 60 G/L (20C)
Specific Gravity/Density:
Molecular Formula: C2H4NO2Na.xH2O
Molecular Weight: 97.05

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, irritating and toxic fumes and gases, carbon dioxide, ammonia.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 6000-44-8: MC1100000 LD50/LC50:
Not available.
Carcinogenicity:
Glycine, Sodium Salt Hydrate - Not listed by ACGIH, IARC, or NTP.
Other:
See actual entry in RTECS for complete information.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 6000-44-8: No information available.
Canada
CAS# 6000-44-8 is listed on Canada's DSL List.
CAS# 6000-44-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 6000-44-8 is listed on the TSCA inventory.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

甘氨酸钠主要用于有机产品的合成、工业洗涤剂的中间体以及生化研究。

化学性质

甘氨酸钠为白色或浅黄色结晶性粉末，具有吸湿性，易溶于水。

作用

• 抑制脊椎索神经递质，NMDA受体变构调控因子。
• 用于有机产品的合成、工业洗涤剂的中间体以及生化研究。

反应信息

• 作为反应物：
  描述：

  sodium glycinate 在 三乙胺 、 三氯化磷 作用下， 以 乙二醇二甲醚 为溶剂， 生成
  参考文献：
  名称：

  Interesting differences between the protonated and sodium adducts of pentacoordinated bisaminoacylspirophosphoranes in electrospray ionization mass spectrometry

  摘要：

  DOI：

  10.1002/jms.432
• 作为产物：
  描述：

  N-甲基-2-羟基乙胺 在 Pd-doped copper catalyst on active carbon sodium hydroxide 作用下， 以 水 为溶剂， 160.0 ℃ 、1.2 MPa 条件下， 以96.7%的产率得到sodium glycinate
  参考文献：
  名称：

  Process for Preparing Creatine, Creatine Monohydrate or Guanidinoacetic Acid

  摘要：

  提出了一种生产肌酸、肌酸单水合物或胍基乙酸的过程，其中首先在碱性溶液中分别催化脱氢N-甲基乙醇胺或乙醇胺，然后用胍基化剂（例如O-烷基异脲或氰胺）在酸性条件下与以这种方式获得的肌氨酸盐或甘氨酸盐溶液最终反应。通过这种方式，可以获得高产率和非常良好纯度的产品，与先前技术相比，不含任何氰化氢、甲醛、氯乙酸或氨的痕迹。也避免了毒理学上关键的二氢三嗪的形成。

  公开号：

  US20090163739A1
• 作为试剂：
  描述：

  N-(o-tolyl)benzothioamide 在 4-二甲氨基吡啶 、 氯双(二甲基乙二肟)[4-(二甲基氨基)吡啶]钴(III) 、 [Ni(2,2'-bipyridine)₃][PF₆]₂ 、 sodium glycinate 作用下， 以 乙腈 为溶剂， 反应 12.0h， 以99%的产率得到4-甲基-2-苯基-1,3-苯并噻唑
  参考文献：
  名称：

  External Oxidant-Free Oxidative Cross-Coupling: A Photoredox Cobalt-Catalyzed Aromatic C–H Thiolation for Constructing C–S Bonds

  摘要：

  An external oxidant-free oxidative coupling for aromatic C-H thiolation by visible-light photoredox cobalt-catalysis has been developed. Various substrates could afford benzothiazoles in good to excellent yields, and only H2 is generated as a side product. When catalytic TBAOH was used as the base, not only 2-aryl but also 2-alkylbenzothiazoles could be obtained through this novel dehydrogenative coupling reaction. This method could be scaled up and applied to the synthesis of biologically active molecules bearing benzothiazole structural scaffolds (potent antitumor agents). Furthermore, the unexpected oxidation byproduct amides, which are often generated in oxidative cyclization of thiobenzanilides, can be completely avoided. Mechanistic studies showed that the H2 originates from the substrates. The kinetic studies indicate that the interaction between the cobalt catalyst and proton might be involved in the rate-limiting process.

  DOI：

  10.1021/jacs.5b05665

文献信息

• 喹啉酮类化合物及其在药物中应用
  申请人：广东东阳光药业有限公司

  公开号：CN105384687B

  公开（公告）日：2018-05-01

  本发明涉及喹啉酮类化合物及其在药物中的应用，具体涉及一种新的喹啉酮类化合物及其药物组合物，以及所述化合物或所述药物组合物在制备药物中的用途；所述药物用于防护、处理、治疗或减轻患者HIF相关和/或EPO相关的疾病，其中，所述HIF相关和/或EPO相关的疾病包括贫血、血管疾病、心肌局部缺血、代谢障碍或伤口愈合等。
• 一种呋喃[2，3-c]并吡啶衍生物及其制备方法 和用途
  申请人：济南新科医药科技有限公司

  公开号：CN110305143B

  公开（公告）日：2021-03-09

  本发明公开了一类强效的脯氨酰羟化酶抑制剂，本发明涉及具有式I结构的化合物，还涉及其药学上可接受的盐和溶剂合物。本发明还涉及含有式I结构化合物的药物组合物及其制药用途。通过抑制脯氨酰羟化酶活性可有效治疗贫血的相关疾病。
• Synthesis and anti-inflammatory activity of acetylsalicylamino acids and peptides
  作者：Sh. Kh. Khalikov、M. Kodirov、S. V. Alieva

  DOI：10.1007/s10600-006-0079-5

  日期：2006.3

  Several water-soluble acetylsalicylamino acids and peptides containing neutral and acidic amino acids were synthesized and investigated for anti-inflammatory activity.

  合成了若干种含水溶性乙酰水杨酰的氨基酸及中性和酸性氨基酸的肽，并对其抗炎活性进行了研究。
• [EN] NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE<br/>[FR] DÉRIVÉS DE NAPHTHYRIDINE EN TANT QU'INHIBITEURS D'UN FACTEUR INDUCTIBLE PAR L'HYPOXIE
  申请人：FIBROGEN INC

  公开号：WO2012106472A1

  公开（公告）日：2012-08-09

  The present disclosure relates to novel compounds, methods, and compositions capable of inhibiting HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).

  本公开涉及能够抑制HIF羟化酶活性的新化合物、方法和组合物，从而增加缺氧诱导因子（HIF）的稳定性和/或活性。
• [EN] GELDANAMYCIN AND DERIVATIVES INHIBIT CANCER INVASION AND IDENTIFY NOVEL TARGETS<br/>[FR] GELDANAMYCINE ET SES DERIVES POUVANT INHIBER UNE PROLIFERATION CANCEREUSE ET IDENTIFIER DE NOUVELLES CIBLES
  申请人：VAN ANDEL RES INST

  公开号：WO2005095347A1

  公开（公告）日：2005-10-13

  Geldanamycin derivatives that block the uPA-plasmin network and inhibit growth and invasion by glioblastoma cells and other tumors at femtomolar concentrations are potentially highly active anti-cancer drugs. GA and various 17-amino-17-demethoxygelddanamycin derivatives are disclosed that block HGF/SF-mediated Met tyrosine kinase receptor-dependent uPA activation at fM levels. Other ansamycins (macbecins I and II), GA derivatives, and radicicol required concentrations several logs higher (≥nM) to achieve such inhibition. The inhibitory activity of tested compounds was discordant with the known ability of drugs of this class to bind to hsp90, indicating the existence of a novel target(s) for HGF/SF -mediated events in tumor development. Methods of using such compounds to inhibit cancer cell activities and to treat tumors are disclosed. Such treatment with low doses of these highly active compounds provide an option for treating various Met-expressing tumors, in particular invasive brain cancers, either alone or in combination with conventional surgery, chemotherapy, or radiotherapy.

  盖尔达霉素衍生物可以在飞托摩尔浓度下阻断uPA-纤溶酶网络，抑制胶质母细胞瘤细胞和其他肿瘤的生长和侵袭，潜在地是高活性的抗癌药物。已披露了盖尔达霉素（GA）和各种17-氨基-17-去甲氧基盖尔达霉素衍生物，可以在飞托摩尔水平下阻断HGF/SF介导的Met酪氨酸激酶受体依赖的uPA激活。其他吖丝霉素类化合物（马克贝辛I和II）、盖尔达霉素衍生物和雷地可（radicicol）需要更高几个数量级（≥nM）的浓度才能实现这种抑制作用。经测试的化合物的抑制活性与该类药物已知结合到hsp90的能力不符，表明存在一种新的靶标，用于抑制HGF/SF介导的肿瘤发展事件。公开了使用这类化合物来抑制癌细胞活动和治疗肿瘤的方法。用这些高活性化合物的低剂量进行治疗为治疗各种表达Met的肿瘤提供了一种选择，特别是侵袭性脑癌，可以单独使用或与常规手术、化疗或放疗结合使用。